Biomarkers, Cancer Therapy & Clinical Research

Genomic Biomarkers

Genomic biomarkers, derived from an individual’s genetic makeup, are central to the advancement of personalized and precision medicine. These biomarkers reveal genetic variations that influence disease risk, progression, and individual responses to therapeutic interventions. Rapid advances in genomic sequencing and bioinformatics have enabled the identification of clinically relevant genetic markers, ranging from cancer susceptibility genes such as BRCA1 and BRCA2 to pharmacogenomics variants that affect drug metabolism, safety, and efficacy. Through genomic analysis, clinicians can assess disease predisposition, guide preventive strategies, and select the most effective therapies for each patient. Genomic biomarkers also support early disease detection through population screening, prenatal testing, and hereditary risk assessment programs. In oncology, they underpin targeted therapies and precision treatment approaches, leading to improved survival outcomes and enhanced quality of life. As genomic science continues to evolve, the integration of genomic biomarkers into clinical practice is reshaping healthcare by enabling more predictive, preventive, and patient-centered medical care.